Ignite Creation Date:
2025-12-24 @ 5:59 PM
Ignite Modification Date:
2025-12-29 @ 12:11 AM
Study NCT ID:
NCT01332968
Status:
COMPLETED
Last Update Posted:
2022-08-11
First Post:
2011-04-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Sponsor:
Hoffmann-La Roche